245 related articles for article (PubMed ID: 26366881)
21. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
22. Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease.
Selting KA; Sharp CR; Ringold R; Knouse J
Vet Comp Oncol; 2015 Dec; 13(4):373-84. PubMed ID: 23859156
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.
Thamm DH; Kamstock DA; Sharp CR; Johnson SI; Mazzaferro E; Herold LV; Barnes SM; Winkler K; Selting KA
Vet Comp Oncol; 2012 Dec; 10(4):292-302. PubMed ID: 22236280
[TBL] [Abstract][Full Text] [Related]
24. Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.
Wang L; Sharif H; Saellström S; Rönnberg H; Eriksson S
BMC Vet Res; 2021 Sep; 17(1):316. PubMed ID: 34579716
[TBL] [Abstract][Full Text] [Related]
25. Liquid chromatography-tandem mass spectrometry method for quantification of thymidine kinase activity in human serum by monitoring the conversion of 3'-deoxy-3'-fluorothymidine to 3'-deoxy-3'-fluorothymidine monophosphate.
Faria M; Halquist MS; Kindt E; Li W; Karnes HT; O'Brien PJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 907():13-20. PubMed ID: 22995377
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.
Boyé P; Floch F; Serres F; Geeraert K; Clerson P; Siomboing X; Bergqvist M; Sack G; Tierny D
J Vet Intern Med; 2019 Jul; 33(4):1728-1739. PubMed ID: 31129922
[TBL] [Abstract][Full Text] [Related]
27. Plasma thymidine kinase activity in dogs with lymphoma and leukemia.
Nakamura N; Momoi Y; Watari T; Yoshino T; Tsujimoto H; Hasegawa A
J Vet Med Sci; 1997 Oct; 59(10):957-60. PubMed ID: 9362053
[TBL] [Abstract][Full Text] [Related]
28. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
[TBL] [Abstract][Full Text] [Related]
29. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation.
Gatt ME; Goldschmidt N; Kalichman I; Friedman M; Arronson AC; Barak V
Anticancer Res; 2015 May; 35(5):3019-26. PubMed ID: 25964590
[TBL] [Abstract][Full Text] [Related]
30. Serum Thymidine Kinase 1, Canine-C-Reactive Protein, Haptoglobin, and Vitamin D Concentrations in Dogs with Immune-Mediated Hemolytic Anemia, Thrombocytopenia, and Polyarthropathy.
Grobman M; Outi H; Rindt H; Reinero C
J Vet Intern Med; 2017 Sep; 31(5):1430-1440. PubMed ID: 28804921
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma.
Wang L; Unger L; Sharif H; Eriksson S; Gerber V; Rönnberg H
BMC Mol Cell Biol; 2021 Dec; 22(1):59. PubMed ID: 34906077
[TBL] [Abstract][Full Text] [Related]
32. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a sandwich ELISA for use in measuring concentrations of canine surfactant protein A in serum of dogs.
Sone K; Akiyoshi H; Aoki M; Sugii S; Ohashi F
Am J Vet Res; 2011 Jun; 72(6):833-7. PubMed ID: 21627531
[TBL] [Abstract][Full Text] [Related]
34. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.
Nisman B; Nechushtan H; Biran H; Gantz-Sorotsky H; Peled N; Gronowitz S; Peretz T
J Thorac Oncol; 2014 Oct; 9(10):1568-72. PubMed ID: 25521401
[TBL] [Abstract][Full Text] [Related]
35. Sensitive nonradiometric method for determining thymidine kinase 1 activity.
Ohrvik A; Lindh M; Einarsson R; Grassi J; Eriksson S
Clin Chem; 2004 Sep; 50(9):1597-606. PubMed ID: 15247154
[TBL] [Abstract][Full Text] [Related]
36. A monoclonal antibody specific for human thymidine kinase 1.
Zhang F; Shao X; Li H; Robison JG; Murray BK; O'Neill KL
Hybridoma; 2001 Feb; 20(1):25-34. PubMed ID: 11289224
[TBL] [Abstract][Full Text] [Related]
37. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease.
von Euler H; Einarsson R; Olsson U; Lagerstedt AS; Eriksson S
J Vet Intern Med; 2004; 18(5):696-702. PubMed ID: 15515587
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
Carlsson L; Larsson A; Lindman H
Ups J Med Sci; 2009; 114(2):116-20. PubMed ID: 19396699
[TBL] [Abstract][Full Text] [Related]
39. Serum amyloid A is not a marker for relapse of multicentric lymphoma in dogs.
Merlo A; Rezende BC; Franchini ML; Monteiro PR; Lucas SR
Vet Clin Pathol; 2008 Mar; 37(1):79-85. PubMed ID: 18366549
[TBL] [Abstract][Full Text] [Related]
40. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
